# A Study of Tucatinib (MK-7119) in Combination With Trastuzumab and Capecitabine in Participants With Previously Treated Locally Advanced Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Carcinoma (MK-7119-001)

> **NCT04721977** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Pfizer** · enrollment: 66 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Tucatinib
- **BIOLOGICAL:** Trastuzumab
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT04721977
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-04-08
- **Primary completion:** 2023-07-17
- **Final completion:** 2026-06-30
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2026-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04721977

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04721977, "A Study of Tucatinib (MK-7119) in Combination With Trastuzumab and Capecitabine in Participants With Previously Treated Locally Advanced Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Carcinoma (MK-7119-001)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04721977. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*